Ajulemic acid  (Synonyms: Lenabasum; IP 751)

IP 751 is a synthetic orally available analogue of a metabolite of Δ9-tetrahydrocannabinol, acts as a cannabinoid receptor agonist, with K_is of 5.7 nM, 56.1 nM and EC₅₀s of 11.6 nM, 13.4 nM for hCB1 and hCB2 receptors, respectively, and has anti-inflammatory property.

Ki: 5.7 nM (hCB1 receptor), 56.1 nM (hCB2 receptor)^[1]
EC50: 11.6 nM (hCB1 receptor), 13.4 nM (hCB2 receptor)^[1]

IP 751 (CT-3; Ajulemic acid) is a synthetic analogue of a metabolite of Δ9-tetrahydrocannabinol, acts as a cannabinoid receptor agonist, with K_is of 5.7 nM, 56.1 nM and EC₅₀s of 11.6 nM, 13.4 nM for hCB1 and hCB2 receptors, respectively, and has anti-inflammatory property^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

IP 751 (0.1-1 mg/kg, p.o.) causes reversal of hyperalgesia in a dose-dependent manner, with a maximal reversal of 63%, ED₅₀ value of 0.5 mg/kg in a model of neuropathic pain in the rat, and a maximal reversal of 57%, ED₅₀ value of 0.7 mg/kg in a model of inflammatory pain in the rat. However, IP 751 (1, 3, 10 mg/kg, p.o.) shows less potent in the tetrad tests than in the chronic pain models, with ED₅₀s of 5.3 mg/kg, 2.3 mg/kg and 4.3 mg/kg in the rotarod, catalepsy and tail-flick assays, respectively.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

400.55

C₂₅H₃₆O₄

137945-48-3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Dyson A, et al. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain. 2005 Jul;116(1-2):129-37.  [Content Brief]